Multicenter, observational clinical study of abatacept in Japanese patients with rheumatoid arthritis

Abstract

The aim of this study was to assess abatacept in rheumatoid arthritis (RA) patient. Patients (20 men, 89 women, aged 61.9 ± 10.4 y) who responded inadequately to conventional synthetic disease-modifying anti-rheumatic drug were treated with abatacept for 24-months. Disease activity score in 28 joints (DAS28-CRP) was evaluated. Of 109 patients, 82 (75.2%) were on methotrexate (MTX; mean dosage 9.0 ± 2.7 mg/week); 48 (44.0%) were naive to biologics and 61 (56.0%) had failed biologics. The 1-and 2-year retention rates were 77% and 53%, respectively. At 24months, the DAS28-CRP remission rates were 62.8% in the biologic-naïve patients, and 33.3% in the biologic-failure patients (p < .01), while the structural remission rates were 83.9% and 73.1%, respectively (p ¼ .461). Abatacept was equally effective in RA patients who were and were not on concomitant MTX. Biologic-naïve was associated with better clinical outcome. Abatacept was effective in patients who showed decreasing anti-CCP antibody titers or serum MMP-3 levels during treatment. Infection was the most frequent adverse effect of abatacept therapy. In conclusion, abatacept is more effective in biologic-naïve than in biologic-failure RA patients with or without concomitant use of MTX. Abatacept is more effective in RA patients with than without decreasing serum MMP-3 or anti-CCP antibody titers during treatment. ARTICLE HISTORY

Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study

“…As previously reported with abatacept [ 10 , 25 , 26 , 36 ] and other bDMARDs [ 37 , 38 ], the clinical outcomes reported here were higher in biologic-naïve patients than in those with failure of prior biologic treatments and may suggest a greater benefit of earlier treatment [ 4 ]. The results from a study with tocilizumab showed equal efficacy in biologic-naïve patients as those with 1 or 2 previous bDMARD failures; however, overall treatment effectiveness was lower in those with > 2 failures [ 32 ].…”

Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study

“…Moreover, in other studies, infections were the second reported AEs for GOL and the most frequent AE for ABT [76,77]. Regarding skin disorders, it is well known that anti-TNFα drugs play a role in the onset of dermatological manifestations, including urticaria, erythema and dermatitis, with a frequency ranging between 10-60% [78,79].…”

Abatacept is Efficacious in the Treatment of Older Patients with csDMARD-Refractory Rheumatoid Arthritis: A Prospective, Multicenter, Observational Study

“…Nonetheless, disease activity was significantly reduced in the AO group; notably, steroid dose was also reduced in a manner similar to that observed in the AY group. Unlike the synergistic effects of tumor necrosis factor inhibitors, the efficacy of abatacept is not substantially enhanced when it is administered in combination with MTX [29][30][31][32][33]. Of note, there appears to be a benefit of MTX in combination with abatacept for patients with greater disease activity or during long-term treatment [34][35][36].…”